A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias

被引：0
|
作者：
Tara L. Lin
Laura F. Newell
Robert K. Stuart
Laura C. Michaelis
Eric Rubenstein
Helen S. Pentikis
Timothy Callahan
Donna Alvarez
Barry D. Liboiron
Lawrence D. Mayer
Qi Wang
Kamalika Banerjee
Arthur C. Louie
机构：
[1] University of Kansas Medical Center,Hollings Cancer Center
[2] Knight Cancer Institute,undefined
[3] Oregon Health and Science University,undefined
[4] Medical University of South Carolina,undefined
[5] Medical College of Wisconsin,undefined
[6] Oncology and Hematology Specialists,undefined
[7] Franciscan Health,undefined
[8] SAJE Consulting,undefined
[9] Biomedical Systems,undefined
[10] Celator/Jazz Pharmaceuticals,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Acute myeloid leukemia; Acute lymphoblastic leukemia; Cardiac repolarization; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：163 / 173
页数：10
相关论文
共 50 条
  • [1] A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
    Lin, Tara L.
    Newell, Laura F.
    Stuart, Robert K.
    Michaelis, Laura C.
    Rubenstein, Eric
    Pentikis, Helen S.
    Callahan, Timothy
    Alvarez, Donna
    Liboiron, Barry D.
    Mayer, Lawrence D.
    Wang, Qi
    Banerjee, Kamalika
    Louie, Arthur C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (01) : 163 - 173
  • [2] V2 THERAPY: VENETOCLAX WITH VYXEOS (CPX-351) FOR ACUTE MYELOID LEUKEMIAS IN YOUNG PATIENTS
    Agresta, Laura
    Young, Jennifer
    Breese, Erin
    Phillips, Christine
    Burns, Karen
    Mizukawa, Benjamin
    Lee, Lynn
    Norris, Robin
    O'Brien, Maureen
    Perentesis, John
    Absalon, Michael
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S187 - S188
  • [3] CPX-351 Population Pharmacokinetics in Pediatric and Adult Patients with Acute Myeloid Leukemia (AML)
    Wang, Qi
    Cooper, Todd M.
    Absalon, Michael J.
    Kolb, E. Anders
    Vasilinin, Grygoriy
    Gosselin, Nathalie H.
    Alonzo, Todd A.
    Marier, J. F.
    BLOOD, 2020, 136
  • [4] Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)
    Kadia, Tapan M.
    Borthakur, Gautam
    Takahashi, Koichi
    DiNardo, Courtney D.
    Daver, Naval
    Pemmaraju, Naveen
    Jabbour, Elias
    Jain, Nitin
    Short, Nicholas J.
    Qiao, Wei
    Adewale, Lade
    Rausch, Caitlin R.
    Pierce, Sherry A.
    Alvarado, Yesid
    Alousi, Amin M.
    Popat, Uday R.
    Khouri, Issa F.
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    BLOOD, 2020, 136
  • [5] CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib Study
    Bataller, Alex
    Bazinet, Alexandre
    Borthakur, Gautam
    Short, Nicholas J.
    Jabbour, Elias
    Takahashi, Koichi
    Daver, Naval
    Issa, Ghayas C.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    BLOOD, 2023, 142
  • [6] Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
    Jen, Wei-Ying
    DiNardo, Courtney D.
    Chien, Kelly S.
    Alvarado-Valero, Yesid
    Masarova, Lucia
    Brandt, Mark
    Bull-Linderman, Debra
    Daver, Naval
    Montalban-Bravo, Guillermo
    Bataller, Alex
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Alousi, Amin
    Short, Nicholas J.
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2023, 142
  • [7] Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality
    Ghayas C. Issa
    Hagop M. Kantarjian
    Lianchun Xiao
    Jing Ning
    Yesid Alvarado
    Gautam Borthakur
    Naval Daver
    Courtney D. DiNardo
    Elias Jabbour
    Prithviraj Bose
    Nitin Jain
    Tapan M. Kadia
    Kiran Naqvi
    Naveen Pemmaraju
    Koichi Takahashi
    Srdan Verstovsek
    Micheal Andreeff
    Steven M. Kornblau
    Zeev Estrov
    Alessandra Ferrajoli
    Guillermo Garcia-Manero
    Maro Ohanian
    William G. Wierda
    Farhad Ravandi
    Jorge E. Cortes
    Leukemia, 2020, 34 : 2914 - 2924
  • [8] A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 ( Part 1) and Palbociclib with CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
    Keiffer, Gina
    Calabretta, Bruno
    Mazo, Alexander
    Outschoorn, Ubaldo Martinez
    Alpdogan, Onder
    Binder, Adam F.
    Porcu, Pierluigi
    Wilde, Lindsay
    Kasner, Margaret
    BLOOD, 2023, 142
  • [9] V2 Trial: A phase I study of venetoclax and CPX-351 for young patients with relapsed/refractory acute leukemia.
    Agresta, Laura
    O'Brien, Maureen Megan
    O'Brien, Eric Justin
    Norris, Robin Elizabeth
    Breese, Erin Haag
    Burns, Karen Cristly
    Mizukawa, Benjamin
    Ryan, Thomas D.
    Desai, Pankaj B.
    Vinks, A. A.
    Grimes, H. Leighton
    Absalon, Michael
    Perentesis, John Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality
    Issa, Ghayas C.
    Kantarjian, Hagop M.
    Xiao, Lianchun
    Ning, Jing
    Alvarado, Yesid
    Borthakur, Gautam
    Daver, Naval
    DiNardo, Courtney D.
    Jabbour, Elias
    Bose, Prithviraj
    Jain, Nitin
    Kadia, Tapan M.
    Naqvi, Kiran
    Pemmaraju, Naveen
    Takahashi, Koichi
    Verstovsek, Srdan
    Andreeff, Micheal
    Kornblau, Steven M.
    Estrov, Zeev
    Ferrajoli, Alessandra
    Garcia-Manero, Guillermo
    Ohanian, Maro
    Wierda, William G.
    Ravandi, Farhad
    Cortes, Jorge E.
    LEUKEMIA, 2020, 34 (11) : 2914 - 2924
12345